Bioactive oat β-glucan reduces LDL cholesterol in Caucasians and non-Caucasians

Thomas M S Wolever, Alison L Gibbs, Jennie Brand-Miller, Alison M Duncan, Valerie Hart, Benoît Lamarche, Susan M Tosh, Ruedi Duss, Thomas M S Wolever, Alison L Gibbs, Jennie Brand-Miller, Alison M Duncan, Valerie Hart, Benoît Lamarche, Susan M Tosh, Ruedi Duss

Abstract

Background: There is increasing global acceptance that viscous soluble fibers lower serum LDL cholesterol (LDL-C), but most evidence for this comes from studies in Caucasians. To see if oat β-glucan lowers LDL-C in Caucasians and non-Caucasians we conducted a post-hoc analysis of the results of a randomized, controlled, double-blind, multi-center clinical trial whose primary aim was to determine if molecular-weight (MW) influenced the LDL-C-lowering effect of oat β-glucan.

Results: Caucasian and non-Caucasian subjects with LDL-C-C ≥ 3.0 and ≤ 5.0 mmol/L (n = 786 screened, n = 400 ineligible, n = 19 refused, n = 367 randomized, n = 345 completed, n = 1 excluded for missing ethnicity) were randomly assigned to consume cereal containing wheat-fiber (Control, n = 74:13 Caucasian:non-Caucasian) or 3 g high-MW (3H, 2,250,000 g/mol, n = 67:19), 4 g medium-MW (4 M, 850,000 g/mol, n = 50:17), 3 g medium-MW (3M, 530,000 g/mol, n = 54:9) or 4 g low-MW (4 L, 210,000 g/mol, n = 51:12) oat β-glucan daily for 4 weeks. LDL-C after 4 weeks was influenced by baseline LDL-C (p < 0.001) and treatment (p = 0.003), but not ethnicity (p = 0.74). In all subjects, compared to control, 3 H, 4 M and 3 M reduced LDL-C significantly by 4.8 to 6.5%, but 4 L had no effect. Compared to control, the bioactive oat β-glucan treatments (3H, 4M and 3M) reduced LDL-C by a combined mean (95% CI) of 0.18 (0.06, 0.31) mmol/L (4.8%, n = 171, p = 0.004) in Caucasians, a value not significantly different from the 0.37 (0.09, 0.65) mmol/L (10.3%, n = 45, p = 0.008) reduction in non-Caucasians.

Conclusion: We conclude that oat β-glucan reduces LDL-C in both Caucasians and non-Caucasians; there was insufficient power to determine if the magnitude of LDL-C-lowering differed by ethnicity.

Trial registration: ClinicalTrials.gov: NCT00981981.

Figures

Figure 1
Figure 1
Time course of unadjusted percent changes from baseline of LDL-C in Caucasian (C) and non-Caucasian (N) subjects randomly assigned to consume the control cereal (Cont, C:N n = 74:13), or cereals containing 4 g low-MW oat β-glucan (4 L, C:N n = 51:12), 3 g medium-MW oat β-glucan (3 M, C:N n = 54:9), 4 g medium-MW oat β-glucan (4 M, C:N n = 50:17) or 3 g high-MW oat β-glucan (3 H, C:N n = 67:19) daily for 4 weeks. Values represent means ± SEM.
Figure 2
Figure 2
Difference in LDL-C, adjusted for baseline, in Caucasian (C, filled bars) and non-Caucasian (N, open bars) subjects after 4 weeks on cereals containing 4 g low-MW oat β-glucan (4 L, C:N n = 51:12), 3 g medium-MW oat β-glucan (3 M, C:N n = 54:9), 4 g medium-MW oat β-glucan (4 M, C:N n = 50:17) or 3 g high-MW oat β-glucan (3 H, C:N n = 67:19) daily versus mean adjusted-LDL-C after 4 weeks on Control in the same ethnic group. Values are means ± 95% CI.

References

    1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349:1269–1276. doi: 10.1016/S0140-6736(96)07493-4.
    1. Murray CJL, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet. 1997;349:1347–1352. doi: 10.1016/S0140-6736(96)07494-6.
    1. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis. Clin Thera. 2009;31:236–244. doi: 10.1016/j.clinthera.2009.02.017.
    1. Bazzano LA, He J, Ogden LG, Loria CM, Whelton PK. Dietary fiber intake and reduced risk of coronary heart disease in US men and women: the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med. 2003;163:1897–1904. doi: 10.1001/archinte.163.16.1897.
    1. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30–42.
    1. Wolever TMS, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V, Lamarche B, Thomson BA, Duss R, Wood PJ. Physicochemical properties of oat β-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. Am J Clin Nutr. 2010;92:723–732. doi: 10.3945/ajcn.2010.29174.
    1. Wood PJ, Beer MU, Butler G. Evaluation of role of concentration and molecular weight of oat β-glucan in determining effect of viscosity on plasma glucose and insulin following an oral glucose load. Brit J Nutr. 2000;84:19–23.
    1. O'Meara JG, Kardia SLR, Armon JJ, Brown CA, Boerwinkle E, Turner ST. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Int Med. 2011;164:1313–1318.
    1. Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, Rotter JI, Nickerson DA, Yang H, Saad M, Krauss RM. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study. Am J Cardiol. 2006;97:843–850. doi: 10.1016/j.amjcard.2005.09.134.
    1. Mangravite LM, Medina MW, Cui J, Pressman S, Smith JD, Rieder MJ, Guo X, Nickerson DA, Rotter JI, Krauss RM. Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Arterioscler Thromb Vasc Biol. 2010;30:1485–1492. doi: 10.1161/ATVBAHA.110.203273.
    1. Geneau R, Stuckler D, Stachenko S, McKee M, Ebrahim S, Basu S, Chockalingham A, Mwatsama M, Jamal R, Alwan A, Beaglehole R. Raising the priority of preventing chronic diseases: a political process. Lancet. 2010;376:1689–1698. doi: 10.1016/S0140-6736(10)61414-6.
    1. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, Ezzati M. Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol) National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011;377:578–586. doi: 10.1016/S0140-6736(10)62038-7.
    1. Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376:1775–1784. doi: 10.1016/S0140-6736(10)61514-0.
    1. Food Safety & Quality Division, Ministry of Health Malaysia. Guide to nutrition labelling and claims. 2010.
    1. Ohama H, Ikeda H, Moriyama H. In: Nutraceutical and Functional Food Regulations in the United States and Around the World. Bagchi D, editor. Massachusetts: Academic Press; 2008. Health foods and foods with health claims in Japan; pp. 251–280.
    1. Karmally W, Montez MG, Palmas W, Martinez W, Branstetter A, Ramakrishnan R, Holleran SF, Haffner SM, Ginsberg HN. Cholesterol-lowering benefits of oat-containing cereal in Hispanic Americans. J Am Dietet Assoc. 2005;105:967–970. doi: 10.1016/j.jada.2005.03.006.
    1. Maki KC, Beiseigel JM, Jonnalagadda SS, Gugger CK, Reeves MS, Farmer MV, Kaden VN, Rains TM. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. J Am Dietet Assoc. 2010;110:205–214. doi: 10.1016/j.jada.2009.10.037.

Source: PubMed

3
Subscribe